Advanced imaging, nanotech tools in NIH institute’s long-term plan
This article was originally published in The Gray Sheet
Disease prevention, diagnosis and treatment will require major investments in technology development, the National Heart, Lung and Blood Institute says. A new strategic plan calls for public/private collaboration and will help guide NHLBI research priorities for the next 5-10 years. Goals include pinpointing genetic variants and biomarkers linked to specific diseases, developing in vivo molecular imaging methods and probes to study the biology of disease processes, and developing DNA sequencing technology that detects even rare gene variants. The institute aims to help develop new tools in areas ranging from genomics, imaging and nanotechnology to tissue engineering. Nanotechnology, for one, could be used to diagnose and treat vulnerable plaque, to make devices that monitor for the onset of thrombotic or hemorrhagic events, and to create in vivo sensors to monitor patients for sleep apnea. NHLBI also will explore noninvasive imaging techniques for early risk stratification and diagnosis of cardiovascular, lung and blood disorders
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.